Digestive Drugs Market Synopsis:
Digestive Drugs Market Size Was Valued at USD 52.8 Billion in 2023, and is Projected to Reach USD 88.15 Billion by 2032, Growing at a CAGR of 5.9% From 2024-2032.
Digestive drugs market is concerned with medications developed to address issues concerning the GI system. Prokinetics are intended for the management of a wide range of ailments, ranging from gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD, specifically Crohn’s disease and ulcerative colitis) to constipation, diarrhoea and peptic ulcers. Pharmacotherapy of gastrointestinal tract involves drugs that help regulate the physical functions, bring down inflammation, control acid secretion, or supress the symptoms. This is because more people are developing digestive disorders due to the unhealthy life styles, lack of exercise and the increasing stress levels. Biologics and targeted therapies are the trends that continue to define the market as they give better results coupled with fewer side effects than generic medicines.
The market for digestive drugs has been enjoying a steady growth owing to increasing incidence of gastrointestinal disorders. These enzymes, which once upon a time were only used to treat exarchic diseases, are today consumed because of changes in way of living, growth of consumption of processed food and geriatric population suffering from digestive disorders. Further, more understanding about the early detection and treatment of digestive disorders has led to higher sales of prescription as well as OTC drugs. The overall market has a great potential to grow which can be attributed to the increasing rate of improvement of the healthcare systems of the emerging economies and the growing middle income population that will create much demand for these products in the market.
Based on explication of current literature and expert opinion, technological progress and the discovery of new drugs, biologics, and personalized medicine paradigms are changing the approach to treating digestive disorders. For instance, monoclonal antibodies are being employed for chronic diseases including Crohn’s disease as well as ulcerative colitis as a result of the mechanism of action. However, the joint alliances between various companies relating to the R&D have been resulting into development of new products that improve patients’ experience. By the combination of these factors, the digestive drugs market is expected to experience continuous growth in the course of the forecast period.
Digestive Drugs Market Trend Analysis:
Biologics Revolutionizing Digestive Drugs Market
-
Originating from the biologics family increasing numbers are seen to act as market game changers in the field of digestive drugs as curative and efficiency treatments for chronic GI disorders such as Crohn’s disease, ulcerative colitis and IBS. Different from other therapies, biologics target certain areas of the immune system as a way of reducing inflammation and stopping the formation of tissues. Using of these innovative treatments is better to such therapies as it is more effective, has fewer side impacts and treats diseases not only symptoms. This trend is further backed by continuous innovation through research and development to manufacture biosimilar products to make these biological treatments more available and inexpensive across many parts of the world.
Expanding Healthcare Access in Emerging Economies
-
There is also considerable potential for new digestive drugs to capitalise on improved healthcare facilities and increasing healthcare spend in emerging markets of India, China and Brazil. Increased income levels among the middle class has put pressure to the medical industry by demanding efficiency and advanced medical treatments to be implemented. Also, the expansion of the government policies in improving the availability and affordability of the healthcare services are also driving the market growth. Because of the cost-advantaged generic products in the digestive disorder therapeutic class and growing consumer focus on digestive health, established pharmaceutical markets offer significant growth potential for industry players.
Digestive Drugs Market Segment Analysis:
Digestive Drugs Market Segmented on the basis of Type, Drug Class, Application, and Region.
By Type, Branded segment is expected to dominate the market during the forecast period
-
Among the genre, branded drugs are forecasted to retain the largest market share of the anticipative digesting drugs within the forecast period due to their generic features such as high quality, relatively shorter hospitalization time and well proved track record of clinical trials. They include new formulas and specialized treatments, designed for certain gastrointestinal diseases, while containing general features of the intended standard drugs. A high uptake of branded drugs is found especially in the developed world where it is quality and reliability that matter, and not cost.
- Nevertheless there are issues that affects the branded segment of the market such as patent expiration and growing competition from generics and biosimilars markets. Pharmaceutical firm have responded to these threats through aggressive investment in R&D to deliver/roll out new products and to build longer product patents. Utilization of biologics in the branded drugs segment increases that was already a leading segment of the Aiempanyddaelwyd, by contributing highest to the overall revenues.
By Drug Class, 5-aminosalicylates segment expected to held the largest share
-
As the maintenance of IBD, the 5-aminosalicylates drug class should capture the largest market share due to increased use in the treatment of UC and CD. As a result, these drugs offer little inflammation fighting power within the lining of the GI tract and are often preferred for both, initiation and continuation of therapies. Therefore, with the global increase of incidents related to IBD the requirement for 5-ASAs has increased greatly and is complemented by a positive security report.
- Drug manufacturers continue to address some of the challenges associated with these drugs in relation to patient compliance and response to the treatments. Thus, the constant enhancement of delivery systems, including extended-release tablets and enemas, is enhancing the effectiveness of 5-aminosalicylates, while further strengthening their leadership in the segment of digestives.
Digestive Drugs Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
In year 2023, North America holds the largest share of the market with approximately 35% market share. This leadership is attributed to the region’s well-developed health care infrastructure, high incidence of gastrointestinal diseases, and a high level of utilization of innovative therapeutic techniques. Particularly, the U.S. plays a great role in the leadership of the region owing to such factors as the high per capita healthcare expenditure of the country, the developed and competitive pharmaceutical sector of the country, and the elevated awareness of the population of the USA with regard to the problems of digestive health. In addition, the digestive drugs leading market players and the continuous intraregional innovation in drug development place North America at the top of the global digestive drugs market.
Active Key Players in the Digestive Drugs Market
-
AbbVie Inc. (USA)
- Astellas Pharma Inc. (Japan)
- AstraZeneca (UK)
- Bayer AG (Germany)
- Boehringer Ingelheim (Germany)
- Bristol-Myers Squibb (USA)
- Eli Lilly and Company (USA)
- GlaxoSmithKline plc (UK)
- Johnson & Johnson (USA)
- Merck & Co., Inc. (USA)
- Novartis International AG (Switzerland)
- Pfizer Inc. (USA)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Other Active Players
|
Global Digestive Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 52.8 Billion |
|
Forecast Period 2024-32 CAGR: |
5.9% |
Market Size in 2032: |
USD 88.15 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Drug Class |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Digestive Drugs Market by Type
4.1 Digestive Drugs Market Snapshot and Growth Engine
4.2 Digestive Drugs Market Overview
4.3 Branded
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Branded: Geographic Segmentation Analysis
4.4 Generic
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Generic: Geographic Segmentation Analysis
Chapter 5: Digestive Drugs Market by Drug Class
5.1 Digestive Drugs Market Snapshot and Growth Engine
5.2 Digestive Drugs Market Overview
5.3 5-aminosalicylates
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 5-aminosalicylates: Geographic Segmentation Analysis
5.4 GI stimulants
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 GI stimulants: Geographic Segmentation Analysis
5.5 Laxatives
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Laxatives: Geographic Segmentation Analysis
5.6 Antacids
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Antacids: Geographic Segmentation Analysis
5.7 H2 Antagonists
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 H2 Antagonists: Geographic Segmentation Analysis
5.8 Antidiarrheals
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Antidiarrheals: Geographic Segmentation Analysis
5.9 Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Others: Geographic Segmentation Analysis
Chapter 6: Digestive Drugs Market by Application
6.1 Digestive Drugs Market Snapshot and Growth Engine
6.2 Digestive Drugs Market Overview
6.3 Gastroesophageal
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Gastroesophageal: Geographic Segmentation Analysis
6.4 Reflux
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Reflux : Geographic Segmentation Analysis
Chapter 7: Digestive Drugs Market by Disease
7.1 Digestive Drugs Market Snapshot and Growth Engine
7.2 Digestive Drugs Market Overview
7.3 GERD
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 GERD: Geographic Segmentation Analysis
7.4 Irritable Bowel Syndrome
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Irritable Bowel Syndrome: Geographic Segmentation Analysis
7.5 Ulcerative Colitis
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Ulcerative Colitis: Geographic Segmentation Analysis
7.6 Others
7.6.1 Introduction and Market Overview
7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.6.3 Key Market Trends, Growth Factors and Opportunities
7.6.4 Others: Geographic Segmentation Analysis
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Benchmarking
8.1.2 Digestive Drugs Market Share by Manufacturer (2023)
8.1.3 Industry BCG Matrix
8.1.4 Heat Map Analysis
8.1.5 Mergers and Acquisitions
8.2 ABBVIE INC. (USA)
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Role of the Company in the Market
8.2.5 Sustainability and Social Responsibility
8.2.6 Operating Business Segments
8.2.7 Product Portfolio
8.2.8 Business Performance
8.2.9 Key Strategic Moves and Recent Developments
8.2.10 SWOT Analysis
8.3 ASTELLAS PHARMA INC. (JAPAN)
8.4 ASTRAZENECA (UK)
8.5 BAYER AG (GERMANY)
8.6 BOEHRINGER INGELHEIM (GERMANY)
8.7 BRISTOL-MYERS SQUIBB (USA)
8.8 ELI LILLY AND COMPANY (USA)
8.9 GLAXOSMITHKLINE PLC (UK)
8.10 JOHNSON & JOHNSON (USA)
8.11 MERCK & CO. INC. (USA)
8.12 NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.13 PFIZER INC. (USA)
8.14 SANOFI (FRANCE)
8.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
8.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
8.17 OTHER ACTIVE PLAYERS
Chapter 9: Global Digestive Drugs Market By Region
9.1 Overview
9.2. North America Digestive Drugs Market
9.2.1 Key Market Trends, Growth Factors and Opportunities
9.2.2 Top Key Companies
9.2.3 Historic and Forecasted Market Size by Segments
9.2.4 Historic and Forecasted Market Size By Type
9.2.4.1 Branded
9.2.4.2 Generic
9.2.5 Historic and Forecasted Market Size By Drug Class
9.2.5.1 5-aminosalicylates
9.2.5.2 GI stimulants
9.2.5.3 Laxatives
9.2.5.4 Antacids
9.2.5.5 H2 Antagonists
9.2.5.6 Antidiarrheals
9.2.5.7 Others
9.2.6 Historic and Forecasted Market Size By Application
9.2.6.1 Gastroesophageal
9.2.6.2 Reflux
9.2.7 Historic and Forecasted Market Size By Disease
9.2.7.1 GERD
9.2.7.2 Irritable Bowel Syndrome
9.2.7.3 Ulcerative Colitis
9.2.7.4 Others
9.2.8 Historic and Forecast Market Size by Country
9.2.8.1 US
9.2.8.2 Canada
9.2.8.3 Mexico
9.3. Eastern Europe Digestive Drugs Market
9.3.1 Key Market Trends, Growth Factors and Opportunities
9.3.2 Top Key Companies
9.3.3 Historic and Forecasted Market Size by Segments
9.3.4 Historic and Forecasted Market Size By Type
9.3.4.1 Branded
9.3.4.2 Generic
9.3.5 Historic and Forecasted Market Size By Drug Class
9.3.5.1 5-aminosalicylates
9.3.5.2 GI stimulants
9.3.5.3 Laxatives
9.3.5.4 Antacids
9.3.5.5 H2 Antagonists
9.3.5.6 Antidiarrheals
9.3.5.7 Others
9.3.6 Historic and Forecasted Market Size By Application
9.3.6.1 Gastroesophageal
9.3.6.2 Reflux
9.3.7 Historic and Forecasted Market Size By Disease
9.3.7.1 GERD
9.3.7.2 Irritable Bowel Syndrome
9.3.7.3 Ulcerative Colitis
9.3.7.4 Others
9.3.8 Historic and Forecast Market Size by Country
9.3.8.1 Russia
9.3.8.2 Bulgaria
9.3.8.3 The Czech Republic
9.3.8.4 Hungary
9.3.8.5 Poland
9.3.8.6 Romania
9.3.8.7 Rest of Eastern Europe
9.4. Western Europe Digestive Drugs Market
9.4.1 Key Market Trends, Growth Factors and Opportunities
9.4.2 Top Key Companies
9.4.3 Historic and Forecasted Market Size by Segments
9.4.4 Historic and Forecasted Market Size By Type
9.4.4.1 Branded
9.4.4.2 Generic
9.4.5 Historic and Forecasted Market Size By Drug Class
9.4.5.1 5-aminosalicylates
9.4.5.2 GI stimulants
9.4.5.3 Laxatives
9.4.5.4 Antacids
9.4.5.5 H2 Antagonists
9.4.5.6 Antidiarrheals
9.4.5.7 Others
9.4.6 Historic and Forecasted Market Size By Application
9.4.6.1 Gastroesophageal
9.4.6.2 Reflux
9.4.7 Historic and Forecasted Market Size By Disease
9.4.7.1 GERD
9.4.7.2 Irritable Bowel Syndrome
9.4.7.3 Ulcerative Colitis
9.4.7.4 Others
9.4.8 Historic and Forecast Market Size by Country
9.4.8.1 Germany
9.4.8.2 UK
9.4.8.3 France
9.4.8.4 The Netherlands
9.4.8.5 Italy
9.4.8.6 Spain
9.4.8.7 Rest of Western Europe
9.5. Asia Pacific Digestive Drugs Market
9.5.1 Key Market Trends, Growth Factors and Opportunities
9.5.2 Top Key Companies
9.5.3 Historic and Forecasted Market Size by Segments
9.5.4 Historic and Forecasted Market Size By Type
9.5.4.1 Branded
9.5.4.2 Generic
9.5.5 Historic and Forecasted Market Size By Drug Class
9.5.5.1 5-aminosalicylates
9.5.5.2 GI stimulants
9.5.5.3 Laxatives
9.5.5.4 Antacids
9.5.5.5 H2 Antagonists
9.5.5.6 Antidiarrheals
9.5.5.7 Others
9.5.6 Historic and Forecasted Market Size By Application
9.5.6.1 Gastroesophageal
9.5.6.2 Reflux
9.5.7 Historic and Forecasted Market Size By Disease
9.5.7.1 GERD
9.5.7.2 Irritable Bowel Syndrome
9.5.7.3 Ulcerative Colitis
9.5.7.4 Others
9.5.8 Historic and Forecast Market Size by Country
9.5.8.1 China
9.5.8.2 India
9.5.8.3 Japan
9.5.8.4 South Korea
9.5.8.5 Malaysia
9.5.8.6 Thailand
9.5.8.7 Vietnam
9.5.8.8 The Philippines
9.5.8.9 Australia
9.5.8.10 New Zealand
9.5.8.11 Rest of APAC
9.6. Middle East & Africa Digestive Drugs Market
9.6.1 Key Market Trends, Growth Factors and Opportunities
9.6.2 Top Key Companies
9.6.3 Historic and Forecasted Market Size by Segments
9.6.4 Historic and Forecasted Market Size By Type
9.6.4.1 Branded
9.6.4.2 Generic
9.6.5 Historic and Forecasted Market Size By Drug Class
9.6.5.1 5-aminosalicylates
9.6.5.2 GI stimulants
9.6.5.3 Laxatives
9.6.5.4 Antacids
9.6.5.5 H2 Antagonists
9.6.5.6 Antidiarrheals
9.6.5.7 Others
9.6.6 Historic and Forecasted Market Size By Application
9.6.6.1 Gastroesophageal
9.6.6.2 Reflux
9.6.7 Historic and Forecasted Market Size By Disease
9.6.7.1 GERD
9.6.7.2 Irritable Bowel Syndrome
9.6.7.3 Ulcerative Colitis
9.6.7.4 Others
9.6.8 Historic and Forecast Market Size by Country
9.6.8.1 Turkiye
9.6.8.2 Bahrain
9.6.8.3 Kuwait
9.6.8.4 Saudi Arabia
9.6.8.5 Qatar
9.6.8.6 UAE
9.6.8.7 Israel
9.6.8.8 South Africa
9.7. South America Digestive Drugs Market
9.7.1 Key Market Trends, Growth Factors and Opportunities
9.7.2 Top Key Companies
9.7.3 Historic and Forecasted Market Size by Segments
9.7.4 Historic and Forecasted Market Size By Type
9.7.4.1 Branded
9.7.4.2 Generic
9.7.5 Historic and Forecasted Market Size By Drug Class
9.7.5.1 5-aminosalicylates
9.7.5.2 GI stimulants
9.7.5.3 Laxatives
9.7.5.4 Antacids
9.7.5.5 H2 Antagonists
9.7.5.6 Antidiarrheals
9.7.5.7 Others
9.7.6 Historic and Forecasted Market Size By Application
9.7.6.1 Gastroesophageal
9.7.6.2 Reflux
9.7.7 Historic and Forecasted Market Size By Disease
9.7.7.1 GERD
9.7.7.2 Irritable Bowel Syndrome
9.7.7.3 Ulcerative Colitis
9.7.7.4 Others
9.7.8 Historic and Forecast Market Size by Country
9.7.8.1 Brazil
9.7.8.2 Argentina
9.7.8.3 Rest of SA
Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies
Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research
|
Global Digestive Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 52.8 Billion |
|
Forecast Period 2024-32 CAGR: |
5.9% |
Market Size in 2032: |
USD 88.15 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Drug Class |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
